Connect MM Registry as a national reference for United States multiple myeloma patients

Survival data from the Connect MM Registry, which is representative of the national MM population, reflect national trends of improvement. This establishes the Connect MM Registry as a reference for MM survival in the US. AbstractBackgroundThe Surveillance, Epidemiology, and End Results (SEER) database and National Cancer Database (NCDB) show improved overall survival (OS) in patients with multiple myeloma (MM) over the last 15  years. This analysis evaluated the validity of the largely community‐based Connect MM Registry as a national reference for MM.MethodsBaseline disease characteristics and survival in US newly diagnosed MM patients were examined using the Connect MM Registry as well as SEER and NCDB databases. Baseline characteristics predictive of longer survival in Connect MM were also identified.ResultsAs of February 2017, 3011 patients were enrolled in the Connect MM Registry; 2912 were treated. Median age at time of MM diagnosis and age range were numerically similar from 2010 to 2015 across all 3 registries; SEER had a higher representation of nonwhite racial groups than that in the other 2 registries. OS rates suggest proportionate improvement with year of diagnosis among the 3 registries. A Cox proportional hazards model suggests that younger age (
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research

Related Links:

(Dana-Farber Cancer Institute) Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Authors: Jiang Y, Chen J, Chen G Abstract Long noncoding RNAs (lncRNAs) are aberrantly expressed in a variety of cancer types. The lncRNA IGF1R antisense imprinted non-protein coding RNA (IRAIN) is associated with various cancer types, yet the role of IRAIN in multiple myeloma (MM) progression remains unclear. In the present study it was identified that IRAIN may act as a tumor suppressor in MM, whilst microRNA (miR)-125b may promote tumorigenesis. Downregulation of IRAIN significantly increased the expression of miR-125b. Furthermore, by using dual-luciferase reporter assays, IRAIN was identified as a target of mi...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Cancer Gene Therapy, Published online: 05 December 2019; doi:10.1038/s41417-019-0154-2BAG3 regulates multiple myeloma cell proliferation through FOXM1/Rb/E2F axis
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
This study evaluated year ‐to‐year changes in treatment choices in a cohort of patients aged 66 or older in the Surveillance, Epidemiology, and End Results (SEER)‐Medicare registry diagnosed with MM between 2007 and 2011. We found that while the usage of PIs among elderly MM patients increased significantly replacing I MiD‐based regimens (with or without alkylating agents but not with PI) between 2007 and 2011, this significant shift did not increase the proportion of treated patients. AbstractThe landscape of treatment for  multiple myeloma (MM) has significantly changed over the last decade due to&...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Abstract Drug resistance (DR) is a phenomenon characterized by the tolerance of a disease to pharmaceutical treatment. In cancer patients, DR is one of the main challenges that limit the therapeutic potential of the existing treatments. Therefore, overcoming DR by restoring the sensitivity of cancer cells would be greatly beneficial. In this context, mathematical modeling can be used to provide novel therapeutic strategies that maximize the efficiency of anti-cancer agents and potentially overcome DR. In this paper, we present a new multiscale model devoted to the interaction of potential treatments with multiple ...
Source: Mathematical Biosciences - Category: Statistics Authors: Tags: Math Biosci Source Type: research
Dependence on the 26S proteasome is an Achilles’ heel for triple-negative breast cancer (TNBC) and multiple myeloma (MM). The therapeutic proteasome inhibitor, bortezomib, successfully targets MM but often leads to drug-resistant disease relapse and fails in breast cancer. Here we show that a 26S proteasome-regulating kinase, DYRK2, is a therapeutic...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Biological Sciences Source Type: research
ConclusionA frailty assessment with appropriate dose modification for induction therapy should be mandatory for all elderly non-transplant-eligible myeloma patients.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: A frailty assessment with appropriate dose modification for induction therapy should be mandatory for all elderly non-transplant-eligible myeloma patients. PMID: 31788741 [PubMed - as supplied by publisher]
Source: Clin Med Res - Category: Research Authors: Tags: J Cancer Res Clin Oncol Source Type: research
SY Abstract Multiple myeloma causes lytic bone lesions and fractures. The impact of fractures on multiple myeloma survival is unclear. The aim of this study was to evaluate the effect of fractures on survival in multiple myeloma using data from multiple myeloma patients diagnosed in Sweden in the years 1990-2013, identified from the Swedish Cancer Registry. Information on date of birth, multiple myeloma diagnosis, fractures, and death was collected from central registries. A Cox regression model was used to compare survival in patients with and without a fracture at multiple myeloma diagnosis and another Cox mode...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Epidemiology | Myeloma | USA Health